Johnson & Johnson APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Johnson & Johnson (JNJ) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.77 billion for the 12-month period ending 2025-12-28, per its 10-K filed 2026-02-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-02-11
- Johnson & Johnson apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $4.77B, a 127.94% increase from fiscal 2024.
- Johnson & Johnson apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $2.09B, a 4.51% decline from fiscal 2023.
- Johnson & Johnson apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.19B, a 11.07% decline from fiscal 2023.
- Johnson & Johnson apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.47B, a 13.59% increase from fiscal 2022.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|
| 2025-12-28 | $4.77B 10-K · filed 2026-02-11 |
| 2024-12-29 | $2.09B 10-K · filed 2026-02-11 |
| 2023-12-31 | $2.19B 10-K · filed 2026-02-11 |
| 2023-01-01 | $2.47B 10-K · filed 2025-02-13 |
| 2022-01-02 | $2.17B 10-K · filed 2024-02-16 |
| 2021-01-03 | $2.22B 10-K · filed 2023-02-16 |
| 2019-12-29 | $1.93B 10-K · filed 2022-02-17 |
| 2018-12-30 | $1.95B 10-K · filed 2021-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |